BACKGROUND: The aim of the present study was to investigate the role of a multimodality treatment for anaplastic thyroid carcinoma (ATC). METHODS: Clinical data of 40 consecutive patients treated between 1985 and 2009 were retrospectively analyzed. RESULTS: The median survival time (MST) stratified by clinical stage was 6.0 months for stage IVB and 4.2 months for stage IVC. When the stage IVB patients were classified into 2 groups (IVB-a and IVB-b) in accord with the extent of involvement of the tumor, the MST of the patients with IVB-a (9.6 months) was significantly longer than that of patients with IVB-b (4.0 months) (p < .05). The MST of the patients treated with surgery followed by radiation and chemotherapy (13.7 months) tended to be longer compared with the patients treated with 2 or fewer modalities. CONCLUSION: The patients with a less-invasive primary tumor may gain a survival benefit from aggressive multimodality therapeutic approaches.
BACKGROUND: The aim of the present study was to investigate the role of a multimodality treatment for anaplastic thyroid carcinoma (ATC). METHODS: Clinical data of 40 consecutive patients treated between 1985 and 2009 were retrospectively analyzed. RESULTS: The median survival time (MST) stratified by clinical stage was 6.0 months for stage IVB and 4.2 months for stage IVC. When the stage IVB patients were classified into 2 groups (IVB-a and IVB-b) in accord with the extent of involvement of the tumor, the MST of the patients with IVB-a (9.6 months) was significantly longer than that of patients with IVB-b (4.0 months) (p < .05). The MST of the patients treated with surgery followed by radiation and chemotherapy (13.7 months) tended to be longer compared with the patients treated with 2 or fewer modalities. CONCLUSION: The patients with a less-invasive primary tumor may gain a survival benefit from aggressive multimodality therapeutic approaches.
Authors: Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak Journal: Ann Surg Oncol Date: 2021-05-25 Impact factor: 5.344
Authors: E Gallardo; J Medina; J C Sánchez; A Viúdez; E Grande; I Porras; T Ramón Y Cajal; J Trigo; L Iglesias; J Capdevila Journal: Clin Transl Oncol Date: 2020-01-31 Impact factor: 3.405
Authors: William J Gibson; Daniel T Ruan; Vera A Paulson; Justine A Barletta; Glenn J Hanna; Stefan Kraft; Antonio Calles; Matthew A Nehs; Francis D Moore; Amaro Taylor-Weiner; Jeremiah A Wala; Travis I Zack; Thomas C Lee; Fiona M Fennessy; Erik K Alexander; Tom Thomas; Pasi A Janne; Levi A Garraway; Scott L Carter; Rameen Beroukhim; Jochen H Lorch; Eliezer M Van Allen Journal: Clin Cancer Res Date: 2016-10-17 Impact factor: 12.531